Thank you for participating in this webinar.

To claim CE credit, please complete the form below. Approximately 4 weeks after completion, a certificate will be emailed to you.

Contact education@nccn.org with any questions.

*
*
Please rate the extent to which you agree or disagree.
Strongly agreeAgreeDisagreeStrongly disagree
Jeremy S. Abramson, MD, MMSc
Farrukh Awan, MD
Shuo Ma, MD, PhD
*
Please rate the extent to which you agree or disagree.
*
*
Please rate the extent to which you agree or disagree.
Strongly agreeAgreeDisagreeStrongly disagree
Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference
Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action
Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (e.g. assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy)
Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy
*
YesNo
Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference
Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action
Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (e.g. assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy)
Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy
*
Please rate the extent to which you agree or disagree.
Strongly agreeAgreeDisagreeStrongly disagree
Increased my knowledge of the presented topic.
Improved my professional competence and/or performance.
Provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, question and answer).
Provided content that was fair, balanced, and scientifically rigorous.
*
*
Please rate the extent to which you agree or disagree.
Strongly agreeAgreeDisagreeStrongly disagree
I have a better understanding of my role as a member of the health care team
I have a better understanding of the roles of others on the health care team.
My ability to work as part of the health care team is improved.
*
Please provide whole numbers only. Do not provide a range. Enter 0 if you do not see patients.
*
*
*
*
Select all that apply.
*
Select all that apply.
*
*
*
*
*
*